#402 — NMR blood analysis: how heart disease risk, insulin resistance, inflammation, and mortality risk can be assessed from a single blood sample | Jim Otvos, Ph.D.
Jim Otvos, a biophysical chemist, explains how nuclear magnetic resonance (NMR) spectroscopy can measure lipoprotein particles directly, providing more clinically relevant information than standard cholesterol tests. He discusses why LDL particle number (LDL-P) and apolipoprotein B (apoB) are better predictors of cardiovascular risk than LDL cholesterol alone, and confronts the myth that large, 'fluffy' LDL particles are harmless. The conversation also covers how NMR can detect insulin resistance years before blood sugar rises, and introduces GlycA as a marker of chronic low-grade inflammation and the metabolic vulnerability index (MVX) as a predictor of frailty and mortality. Throughout, Otvos reflects on the resistance to adopting NMR diagnostics despite the rich data they yield from a single blood draw.
This summary was generated from show notes and public descriptions, not from a full transcript review. Details may contain inaccuracies.
Canon
•
LDL Particle Number Over Particle Size00:28:45
Large, 'fluffy' LDL particles are not benign; LDL particle number (LDL-P) is the more important predictor of cardiovascular risk, and focusing on particle size alone can be misleading.
GlycA is an NMR-derived measurement of glycoprotein acetylation that reflects chronic low-grade inflammation, and elevated levels independently predict cardiovascular events, cancer, and all-cause mortality.
From Flawed Cancer Test to Lipoprotein Testing00:03:30
Jim Otvos recounts how a failed cancer detection test using NMR in 1986 serendipitously led to the discovery that the technique could instead measure lipoprotein particles, eventually resulting in the first FDA-cleared method for direct LDL particle quantification.
Standard LDL cholesterol (LDL-C) measurements can be discordant with LDL particle number (LDL-P), and this discordance is common in metabolic syndrome and among patients on lipid-lowering therapy, potentially hiding residual risk.
NMR can reveal insulin resistance years before fasting glucose or HbA1c become abnormal, by measuring lipoprotein abnormalities like increased small LDL particles and high triglycerides/HDL ratio.